statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences PR Newswire...

Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences

Company presentation and fireside chat on April 11th at 11:45 a.m. ETCAMBRIDGE, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology...

Foghorn Therapeutics to Participate in Needham's 23rd Annual Virtual Healthcare Conference

Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader...

Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

In trading on Monday, shares of Foghorn Therapeutics Inc (FHTX) crossed below their 200 day moving average of 6.07, changing hands as low as 5.85 per share. Foghorn Therapeutics Inc shares...

FHTX Crosses Below Key Moving Average Level

Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024 Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative...

Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024

We note that the Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) Chief Strategy & Business Operations Officer, Fanny Cavalie...

Have Insiders Sold Foghorn Therapeutics Shares Recently?

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Foghorn Therapeutics expects cash runway into first half of 2026

Foghorn Therapeutics reports FY23 EPS ($2.34), consensus ($2.48)

Dose escalation in FHD-286 combination study in AML continues to progress; clinical data anticipated in the second half of 2024 FHD-909, a first-in-class BRM selective inhibitor, selected for...

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in multiple mouse models of NSCLC; IND filing planned in Q2 2024 Oral...

Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

Volume	48,320.00
52-Wk High	$9.97
52-Wk Low	$2.70

FHTX Foghorn Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals